ストックスクリーナーアプリを入手
3.35
3.72%
0.12
アフターアワーズ：
3.35
前日終値:
$3.23
開ける：
$3.3
24時間の取引高:
834.01K
Relative Volume:
0.83
時価総額：
$672.10M
収益：
$12.99M
当期純損益:
$-74.39M
株価収益率:
-7.6136
EPS:
-0.44
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
-4.56%
1か月 パフォーマンス:
+6.69%
6か月 パフォーマンス:
-7.97%
1年 パフォーマンス:
+16.32%
1日の値動き範囲:
$3.25
$3.37
1週間の範囲:
$3.11
$3.49
52週間の値動き範囲:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.35 | 672.10M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 - MyChesCo
Wells Fargo & Company MN Acquires 21,768 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (ABUS) Showcases Promising Data on Imdusiran and AB-101 | ABUS Stock News - GuruFocus
Arbutus Presents Clinical Trial Data from its Two HBV - GlobeNewswire
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Barclays PLC - Defense World
Invesco Ltd. Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp (ABUS) is a good investment, but the stock may be overvalued - uspostnews.com
Arbutus Biopharma Corp (ABUS) With A Potential Upside Of More Than -139.44% - Stocksregister
Arbutus Biopharma Corp (ABUS) looking to reclaim success with recent performance - Sete News
Legal & General Group Plc Has $388,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp [ABUS] Insider Activity: An Update for Investors - knoxdaily.com
Arbutus Biopharma Corp expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Stock Market Recap: Arbutus Biopharma Corp (ABUS) Concludes at 3.12, a -1.58 Surge/Decline - DWinneX
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress - MyChesCo
Arbutus Biopharma Corp (ABUS)’s stock price in review: A technical analysis - uspostnews.com
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewswire
Alliancebernstein L.P. Has $393,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Vanguard Group Inc. - Defense World
Raymond James Financial Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Wellington Management Group LLP Buys 16,484 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Corebridge Financial Inc. Has $238,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
KLP Kapitalforvaltning AS Invests $84,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Teacher Retirement System of Texas Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters - BUCKSCO.Today
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month - Yahoo Finance
Arbutus Biopharma Corp (NASDAQ: ABUS) – An Analysis Is What You Need - stocksregister.com
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ABUS’s Market Whiplash: 7.03% YTD Rise, 3.86% Rise in 30 Days - investchronicle.com
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MSN
Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Chardan Capital Reiterates “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Arbutus Biopharma earnings beat by $0.02, revenue fell short of estimates - Investing.com
Arbutus stock gains after 57% workforce cuts (ABUS:NASDAQ) - Seeking Alpha
Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? - uspostnews.com
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Arbutus Biopharma Announces 2024 Financial Results and Strategic Restructuring - TipRanks
Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery - MSN
Reviewing Akari Therapeutics (NASDAQ:AKTX) and Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Moderna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges - Yahoo Finance
FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World
Are Arbutus Biopharma Corp’shares a good deal? - US Post News
Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction - Yahoo Finance
Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):